A combination of phosphodiesterase type 5 inhibitor and tamoxifen for acute Peyronie’s disease: the first clinical signals-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A combination of phosphodiesterase type 5 inhibitor and tamoxifen for acute Peyronie’s disease: the first clinical signals

Published:2023-07-04 Issue:8 Volume:20 Page:1057-1059
ISSN:1743-6095
Container-title:The Journal of Sexual Medicine
language:en
Short-container-title:

Author:

Cellek Selim¹²,Megson Matthew¹²³,Ilg Marcus M¹²,Ralph David J¹²³

Affiliation:

1. Fibrosis Research Group , Medical Technology Research Centre, , Chelmsford CM1 1SQ , United Kingdom

2. Anglia Ruskin University , Medical Technology Research Centre, , Chelmsford CM1 1SQ , United Kingdom

3. Urology Department, University College London Hospital , London W1G 8PH , United Kingdom

Publisher

Oxford University Press (OUP)

Subject

Urology,Reproductive Medicine,Endocrinology,Endocrinology, Diabetes and Metabolism,Psychiatry and Mental health

Link

https://academic.oup.com/jsm/article-pdf/20/8/1057/51007769/qdad083.pdf

Reference27 articles.

1. Peyronie’s disease: an outcomes-based guide to non-surgical and novel treatment modalities;Reddy;Res Rep Urol,2023

2. Pathophysiology and future therapeutic perspectives for resolving fibrosis in Peyronie’s disease;Milenkovic;Sex Med Rev,2019

3. Is there a line between ethics and market competition? Lights and shades of the withdrawal of collagenase treatment for Peyronie’s disease;Cocci;Int J Impot Res,2022

4. Clinical significance of shortened penile length and alterations in penile length following treatment for Peyronie’s disease;Goldstein;Sex Med Rev,2022

5. Trends in reported male sexual dysfunction over the past decade: an evolving landscape;Pozzi;Int J Impot Res,2021

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acute Phase Peyronie’s Disease: Where Do We Stand?;Cureus;2024-08-17

2. Commentary on “Phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie’s disease: a retrospective cohort study”;International Journal of Impotence Research;2023-12-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3